Table 1.

Cohort Characteristics by pancreatic status and PERT use among those with PI

	BONUS CF infant Cohort N = 231
	PI + initiated PERT N = 205	PI + no PERT use N = 6	PS N = 20
Fecal Elastase (μg/g)
≤50	144 (70.2%)	1 (16.7%)	0 (0%)
50–≤ 100	25 (12.2%)	0 (0%)	0 (0%)
100–≤ 200	13 (6.3%)	1 (16.7%)	0 (0%)
>200	1 (0.5%)	2 (33.3%)	16 (80%)
Unavailable	22 (10.7%)	2 (33.3%)	4 (20%)
Genotype Class
I–III/I–III	186 (90.7%)	6 (100%)	3 (15%)
IV–V/any	10 (4.9%)	0 (0%)	9 (45%)
I–III/unknown	8 (3.9%)	0 (0%)	8 (40%)
Unknown/unknown	1 (0.5%)	0 (0%)	0 (0%)
Meconium Ileus
Yes	25 (12.2%)	1 (16.7%)	1 (5%)
No	180 (87.8%)	5 (83.3%)	19 (95%)
Birth weight z-score (mean, SD)	−0.19 (0.88)	0.26 (1.17)	0.08 (1.09)
Breastfeeding Status
Excl BF at 3 mos	54 (26.3%)	2 (33.3%)	1 (5%)
BF and FML @ 3 mos	38 (18.5%)	0 (0%)	6 (30%)
Excl FML @ 3 mos	112 (54.6%)	3 (50.0%)	12 (60%)
Acid Blocker Usage
None	61 (29.8%)	5 (83.3%)	12 (60%)
PPI only	34 (16.6%)	0 (0%)	3 (15%)
H2 Blocker only	63 (30.7%)	0 (0%)	5 (25%)
PPI + H2	47 (22.9%)	1 (16.7%)	0 (0%)
Participant specific max PERT dose 0–6 mos
Lipase Units/Kg/Meal
N	205
mean (sd)	1882 (621)
min, max	492, 3727
<1000	18 (8.8%)
1000–2000	99 (48.3%)
>2000	88 (42.9%)
Participant specific max PERT dose 6–12 mos
Lipase Units/Kg/Meal
N	196
mean (sd)	1842 (617)
min, max	313, 3612
<1000	20 (9.8%)
1000–2000	90 (43.9%)
>2000	86 (42.0%)

PI=pancreatic insufficient; PS= pancreatic sufficient; SD=standard deviation; Excl= exclusive; BF=breast fed; FML=formula fed; PPI=proton pump inhibitor